Role of Blood-Brain Barrier in Alzheimer’s Disease
The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
The blood-brain barrier (BBB) is involved in the pathogenesis of Alzheimer's disease (AD). BBB is a highly selective semipermeable structural and chemical barrier which ensures a stable internal environment of the brain and prevents foreign objects invading the brain tissue. BBB dysfunction induces the failure of Aβ transport from brain to the peripheral circulation across the BBB. Especially, decreased levels of LRP-1 (low density lipoprotein receptor-related protein 1) and increased levels of RAGE (receptor for advanced glycation endproducts) at the BBB can cause the failure of Aβ transport. The pathogenesis of AD is related to the BBB structural components, including pericytes, astrocytes, vascular endothelial cells, and tight junctions. BBB dysfunction will trigger neuroinflammation and oxidative stress, then enhance the activity of β-secretase and γ-secretase, and finally promote Aβ generation. A progressive accumulation of Aβ in brain and BBB dysfunction may become a feedback loop that gives rise to cognitive impairment and the onset of dementia. The correlation between BBB dysfunction and tau pathology has been well-reported. Therefore, regulating BBB function may be a new therapeutic target for treating AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661 · cited 2×
“TheBBBhasthemostimpor-tantroleinmaintainingbrainfunctionamongthe threebrainbarriers[14,15].”
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Establishment and Dysfunction of the Blood-Brain Barrier
Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015) · Cell · doi:10.1016/j.cell.2015.10.067 · Cited by 1,670 · cited 1×
“Pericytes, an important component of neurovascular unit and BBB, act like the gatekeepers of the BBB, and exquisitely regulate the movement of brain cellsandthetransportationofnutrientsandmoleculesbetweenthebloodandthebraininterstitialfluidthatsurroundsthebraincells [87–89].”
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier
Huber, J. D., Egleton, R. D., & Davis, T. P. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02004-x · Cited by 786 · cited 1×
“…or progression of numerous brain diseases, such as hemorrhagic and ischemic stroke, intracranial infectious diseases, intracranial autoimmune diseases, epilepsy, lupus cerebritis, and brain tumors [105, 106], as well as neurodegenerative diseases like Parkinson’s disease and AD [45, 107].”
The blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767 · cited 7×
“Second,A (cid:2) pathology suffering from BBB dysfunction can indirectly facilitate the onset of tau pathology, representing a mechanistic link between A (cid:2) /tau deposition after BBB dysfunction [1, 126].”
InfluentialAlzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672 · cited 2×
“528 Yet, the role of BBB in the pathogenesis of AD is 529 still a challenge [12, 132].”
Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670
Halliday, M. R., Rege, S. V., Ma, Q., Zhao, Z., Miller, C. A., Winkler, E. A., & Zlokovic, B. V. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.44 · Cited by 649
Research works printed but not linked: 1
- Volpina, 2015, [Fragment of receptor for advanced glycation end products improves memory state in a model of Alzheimer’s disease, Bioorg Khim, 41, 709
Cited by
Items 301–376 of 376
Alzheimer's disease therapeutics
Sang, Z., & Huang, L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18611-0.00031-0 · Cited by 2
Yuan, R., Yisen, Z., Wang, X., Tang, W., & Wang, W. (2023) · Translational Neuroscience · doi:10.1515/tnsci-2022-0301 · Cited by 1
“BBB dysfunction can lead to impaired transport of Aβ from the cerebral to the peripheral circulation [46].”
BackgroundThe Role of Polyphenols in the Treatment of Alzheimer's Disease: Narrative Review
Alattiya, R. H., Tarish, F. K., Hashim, L. L., & Hussain, S. A. (2021) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v1i.31 · Cited by 3
Janeiro, M. H., Puerta, E., Lanz, M., Milagro, F. I., Ramírez, M. J., & Solas, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.17.469001 · Cited by 1
“Noteworthy, BBB integrity can be disrupted by neuroinflammation associated with many age-related disorders as Alzheimer’s disease (Cai et al., 2018).”
BackgroundApplication of Nanophytomedicine for the Treatment of Central Nervous System Disorders
Rarokar, N. R., Gurav, N. S., & Gurav, S. S. (2023) · Wiley eBooks · doi:10.1002/9781119794127.ch18 · Cited by 2
Predicting emergent phenotypes from single cell populations using CELLECTIONPreprint
Hu, H., Sanghi, S., & Quon, G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.02.673886 · Cited by 1
A is for Autophagy and Alzheimer's
Dow, C. T., & Szepieniec, J. (2018) · OBM Geriatrics · doi:10.21926/obm.geriatr.1804020
Effects of Cytomegalovirus on Pericytes
Alcendor, D. J. (2021) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-030-62129-2_4
Xiang, S., Johnson, T. S., Dong, T., Huang, Z., Cheng, M., Wang, T., Yang, K., Ni, D., Huang, K., & Zhang, J. (2020) · Research Square · doi:10.21203/rs.3.rs-26385/v1
“N8 is involved in gap junction, which supports the assumption that gap junction associated with blood brain barrier may be disrupted in AD to allow the access of virus or bacteria to AD brain (Cai et al., 2018; Devanand, 2018; Montagne et al., 2017; Readhead et al., 2018).”
BackgroundJohnson, T. S., Xiang, S., Dong, T., Huang, Z., Cheng, M., Wang, T., Yang, K., Ni, D., Huang, K., & Zhang, J. (2020) · Research Square · doi:10.21203/rs.3.rs-26385/v2
Johnson, T. S., Xiang, S., Dong, T., Huang, Z., Cheng, M., Wang, T., Yang, K., Ni, D., Huang, K., & Zhang, J. (2020) · Research Square · doi:10.21203/rs.3.rs-92026/v1
The role of the blood-brain barrier in psychiatric disorders
Lačković, M., Ivković, M., Vićentić, S., Jerotić, S., Nestorović, M., Stojković, T., & Pavlovic, A. M. (2022) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh220417081l
Mubeen, H., Masood, A., Zafar, A., Khan, Z. Q., Khan, M. Q., Nisa, A. U., & Naveed, Z. A. (2022) · Research Square · doi:10.21203/rs.3.rs-2060964/v1
Configurable Models of the Neurovascular Unit
Mishra, Y., Sáez, J., & Owens, R. M. (2022) · Springer eBooks · doi:10.1007/978-3-031-11409-0_1
Deng, Y. J., Hong, J., Cao, Y., Kang, N., Han, D.-Y., Li, Y., Chen, L., Li, Z., Zhan, R., Guo, X., et al. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12016
“Because RAGE mediates A β peptide transport across the BBB and accumulation in the brain (13), upregulation of RAGE expression leads to abnormal A β levels in the postoperative ageing brain, as demonstrated in our previous study (29).”
BackgroundMethodDunton, A. D. (2023) · University of North Texas Digital Library (University of North Texas) · doi:10.12794/metadc2179285
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226955
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226976
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226979
Additional file 1 of IL-17A promotes the progression of Alzheimer’s disease in APP/PS1 mice
Cao, M., Liu, J., Zhang, X., Wang, Y., Hou, Y., Song, Q., Cui, Y., Zhao, Y., & Wang, P. (2023) · Figshare · doi:10.6084/m9.figshare.24819513
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226958
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226970
Dizocilpine derivatives with neuroprotective effect lacking the psychomimetic side effectsPreprint
Konecny, J., Misiachna, A., Chvojková, M., Kletečková, L., Kolcheva, M., Novák, M., Prchal, L., Ladislav, M., Hemelíková, K., Netolický, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.17.599304
Nervous System, Neurons, and Metabolism
Konukoğlu, D. (2024) · doi:10.69860/nobel.9786053359166.1
The Gut Microbiota-Alzheimer’s Disease Connection
刘, 泽. (2024) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2024.33164
Moar, K., Deepika, & Maurya, P. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818851-4.00012-5
Shi, R., Li, Y., Mou, L., Zheng, Y., Xia, L., Liu, Y. A. A., Stoika, R. S., Attila Gabor, S. I. K., Liu, K., & Jin, M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5159324
Grossberg, A. N. (2024) · Digital Commons - DU (University of Denver) · doi:10.56902/etdcrp.2024.14
Imaging Alzheimer’s Retinopathy
Gaire, B. P., Koronyo, Y., Shi, H., Rentsendorj, A., Dumitrascu, O. M., Vit, J., Doustar, J., Black, K. L., Fuchs, D.-T. S., & Koronyo‐Hamaoui, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-72156-4_6
He, Y., Li, J., Zhao, K., Shi, L., Zhou, H., Li, Y., Zhao, Q., Ya, J., & Wu, C. (2025) · Research Square · doi:10.21203/rs.3.rs-6395732/v1
Nanoparticle mediated gene therapy for Alzheimer’s disease
Alhajj, L., Nasidi, K. A., Ovenseri, A. C., & Halilu, E. M. (2025) · Journal of Phytomolecules and Pharmacology · doi:10.56717/jpp.2025.v04i01.040 · Cited by 1
Raghuvanshi, S., Mazumder, A., & Das, S. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273378092250623064748 · Cited by 1
The Role of T Cells in Alzheimer's Disease
Lin, Y., Zhao, H., Meng, D., & Wang, M. (2025) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2025061107
Nanocarrier advancements revolutionizing treatment for neurodegenerative diseases
Mohan, D., Sri Bagavathi Perumal, R. B., Hariprakash, S., Anbazhagan, S. V., Priyadharshini, M., Nandhini, S., Vinnarasi, J., Saadaoui, S., Raorane, C. J., & Rajasekharan, S. K. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107584
Soluble epoxide hydrolase in Alzheimer’s disease drives neurovascular dysfunctionPreprint
DeMeglio, M., Biasi, E. S. D., Breunig, P., Candlish, M., Sauerland, C., Günther, S., Kawase, H., Peguera, B., Bohnstaedt, C., Nilsson, P. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.09.692941
“There is, however, agreement that vascular defects and dysfunction of the blood-brain barrier (BBB) are early events in the onset of AD 1 – 5 .”
Liposome-mediated anticancer drug delivery approaches for treatment of brain tumor
Ramarao, E. V. V. S., Abishek, K. G., Kesharwani, P., Sarangi, P. K., Gupta, G., Ramesh, S., Patil, U. K., & Dandela, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33548-8.00010-0
Bhargavan, B., Woollard, S. M., McMillan, J. E., & Kanmogne, G. D. (2021) · Figshare · doi:10.6084/m9.figshare.17065818
Bhargavan, B., Woollard, S. M., McMillan, J. E., & Kanmogne, G. D. (2021) · Figshare · doi:10.6084/m9.figshare.17065821
Chen, S., Guo, D., Zhu, Y., Xiao, S., Xie, J., Zhang, Z., Hu, Y., Huang, J., Ma, X., Ning, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25397542
Chen, S., Guo, D., Zhu, Y., Xiao, S., Xie, J., Zhang, Z., Hu, Y., Huang, J., Ma, X., Ning, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25397692
Additional file 1 of Cellular transcriptional alterations of peripheral blood in Alzheimer’s disease
Song, L., Yang, Y. T., Guo, Q., & Zhao, X.-M. (2022) · Figshare · doi:10.6084/m9.figshare.20705360
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226952
Bhargavan, B., Woollard, S. M., McMillan, J. E., & Kanmogne, G. D. (2021) · Figshare · doi:10.6084/m9.figshare.17065827
Chen, S., Guo, D., Zhu, Y., Xiao, S., Xie, J., Zhang, Z., Hu, Y., Huang, J., Ma, X., Ning, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26692306
Lv, X., Zhang, M., Cheng, Z., Wang, Q., Wang, P., Xie, Q., Ni, M., Shen, Y., Tang, Q., & Gao, F. (2023) · Figshare · doi:10.6084/m9.figshare.22620493
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226949
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226946
Bhargavan, B., Woollard, S. M., McMillan, J. E., & Kanmogne, G. D. (2021) · Figshare · doi:10.6084/m9.figshare.17065824
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226967
Zhao, L.-J., Wang, Z.-T., Ma, Y.-H., Zhang, W., Dong, Q., Yu, J.-T., & Tan, L. (2021) · Figshare · doi:10.6084/m9.figshare.16755740
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226982
Khalafi, M., Rashnoudi, A. R., Rahmani, F., Javanmardi, P., Panahi, P., Kiani Shahvandi, H., Tajik, M. H., Soleimantabar, H., & Shirbandi, K. (2023) · Figshare · doi:10.6084/m9.figshare.22604738
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226961
Bhargavan, B., Woollard, S. M., McMillan, J. E., & Kanmogne, G. D. (2021) · Figshare · doi:10.6084/m9.figshare.17065815
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226973
Chen, S., Guo, D., Zhu, Y., Xiao, S., Xie, J., Zhang, Z., Hu, Y., Huang, J., Ma, X., Ning, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26692303
Functional Disability and MMPs in Alzheimer’s Disease
Alkanlı, N., Alkanlı, S. S., & Ay, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-40858-8_565-1
BPA Improved the Cognitive Dysfunction of Patients with CTEPHPreprint
Gong, S.-G., Sun, Y.-Y., He, J., Wu, W.-H., Zhao, Q., Liu, P., Li, J.-L., Li, H., Luo, C., Qiu, H., et al. (2025) · medRxiv · doi:10.2139/ssrn.5702452
Phototherapeutic Compounds: Toward Cognitive Revival in Alzheimer’s Disease
Kathiresan, D. S., Puthamohan, V. M., & Arun Nagendran., N. (2026) · Springer eBooks · doi:10.1007/978-981-95-4751-7_4 · Cited by 1
Shi, R., Li, Y., Mou, L., Zheng, Y., Xia, L., Liu, Y., Стойка, Р. С., Attila Gabor, S. I. K., Liu, K., & Jin, M. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157813
Ultrasound-Mediated Gene Therapy in Alzheimer’s Disease Validated through In Vivo PET ImagingPreprint
Guo, Y., Foiret, J. L., Ajenjo, J., Malek, R. S., Zhang, N., Seo, J. W., Wang, J., Jan, B. L., Raie, M. N., Tumbale, S. K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.02.703398 · Cited by 1
Yang, H., Li, J., Zhao, K., Shi, L., Zhou, H., Li, Y., Zhao, Q., Ya, J., & Wu, C. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.111819 · Cited by 1
Valverde, A. (2020) · theses.fr (ABES) · doi:10.70675/f1b70734zf4e3z4870z8fbdz950d831642a7
Freyssin, A. (2020) · theses.fr (ABES) · doi:10.70675/0db2e37dz547bz4731z852dz9b843c062cba
An RNA interference strategy for the treatment of Alzheimer's disease
Liu, X. (2021) · theses.fr (ABES) · doi:10.70675/35211b03z3b19z478czb3e2z8d35ab2170d6
Functional Disability and MMPs in Alzheimer’s Disease
Alkanlı, N., Alkanlı, S. S., & Ay, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-11375-7_565
Mechanisms of autophagy–lysosome pathway impairment in Alzheimer's disease
Lü, K., Lu, Y., Tang, R., Dong, X., Zhuang, P., Gao, Y., Cheng, M., Wang, Y., & Wang, Y. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261460879
“181 On the other hand, astrocytes also participate in A β clearance through the secretion of factors such as ApoE, apolipoprotein J (Apo J, aggrecan), α 1-antichymotrypsin, α 2-macroglobulin, etc., and promote the transport of A β across the BBB through receptors such as low-density lipoprotein…”
Shang, Y., Zhai, Z., Cong, L., & Dong, X. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108339 · Cited by 1
Leaky Blood–Brain Barrier and Chronic Pain: The Neuroinflammatory Link
García-Domínguez, M. (2026) · Biology · doi:10.3390/biology15141145
“Disruption of these molecular mechanisms is increasingly recognized as a fundamental pathogenic event in numerous neurological disorders, including ischemic stroke, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, and other neuroinflammatory conditions [102,103].”
Dhal, A., Aviña, A. E., Peng, P.-W., & Yang, T. (2026) · ACS Applied Engineering Materials · doi:10.1021/acsaenm.6c00402
Yang, Z., Xiao, Z., Huang, B., & Wang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1955233 · Cited by 1
Stellos, K., Stamatelopoulos, K., Aivalioti, E., Georgiopoulos, G. A., Delialis, D., Konstantaki, C., Patras, R., Moustou, C., Mpatziou, P., Mavraganis, G., et al. (2026) · Thrombosis and Haemostasis · doi:10.1055/a-2958-4419
High-altitude hypoxia and blood–brain barrier injury: cellular mechanisms and clinical targets
Xu, G., Zhang, Y., Xia, T., Chang, M., Zhang, N., Zhao, Q., Chen, G., Li, Y., Zhang, L., Zhou, W., et al. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.09.027
Ho, T. C., Vignolle, G. A., Wang, D. J. J., & Church, A. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.107028
Impaired peptide amidation and risk of incident dementia in the Malmoe preventive project cohort
Kaufmann, P., Ilina, Y., Giontella, A., Press, M., Nägga, K., Hansson, O., Hampel, H. J., Bergmann, A., & Melander, O. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02173-7
“It is compromised in AD, exacerbating amyloidosis, tauopathy, and neuroinflammation [8, 9].”
Metadata
- Authors
- Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q.
- Affiliations
- Department of Neurology, Chongqing General Hospital, Chongqing, Chongqing, China
- Corresponding author
- Cai, Zhiyou
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-05-30
- Volume
- 63
- Issue
- 4
- Pages
- 1223-1234
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2804234159
- Cited by
- 370
- References
- 133
- Citations by year
- 2026: 31 · 2025: 59 · 2024: 63 · 2023: 69 · 2022: 49 · 2021: 63 · 2020: 25 · 2019: 10 · 2018: 1
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- blood-brain barrier, Alzheimer's disease
- MeSH terms
- Receptor for Advanced Glycation End Products, Alzheimer Disease, Blood-Brain Barrier, Humans, Amyloid beta-Peptides, Low Density Lipoprotein Receptor-Related Protein-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.